Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Performance of Lung Cancer Risk Prediction Models Across Racial and Ethnic Groups in the United States

Study Uncovers How Obesity Influences Molecular Pathways in Breast Cancer Progression

Study Clarifies HPV-Related Cancer Risk in Immunosuppressed Populations

Second Primary Malignancies After T-Cell–Engaging Bispecific Antibody Therapy

Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans